DDInter255 DDInter906
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ifosfamide
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ifosfamide
Busulfan {u} (Compound) downregulates {v} (Gene) NNT
NNT {u} (Gene) is upregulated by {v} (Compound) Ifosfamide
Busulfan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Ifosfamide
Busulfan {u} (Compound) downregulates {v} (Gene) ENOPH1
ENOPH1 {u} (Gene) is downregulated by {v} (Compound) Ifosfamide
Busulfan {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Ifosfamide
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) upregulates {v} (Gene) NNT
NNT {u} (Gene) is upregulated by {v} (Compound) Ifosfamide
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Ifosfamide
Busulfan {u} (Compound) downregulates {v} (Gene) NNT
NNT {u} (Gene) is upregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ifosfamide
Busulfan {u} (Compound) downregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is downregulated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound)
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ifosfamide (Compound)
Busulfan (Compound) downregulates NNT (Gene) and NNT (Gene) is upregulated by Ifosfamide (Compound)
Busulfan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Ifosfamide (Compound)
Busulfan (Compound) downregulates ENOPH1 (Gene) and ENOPH1 (Gene) is downregulated by Ifosfamide (Compound)
Busulfan (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound)
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) upregulates NNT (Gene) and NNT (Gene) is upregulated by Ifosfamide (Compound)
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Ifosfamide (Compound)
Busulfan (Compound) downregulates NNT (Gene) and NNT (Gene) is upregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound)
Busulfan (Compound) downregulates TATDN2 (Gene) and TATDN2 (Gene) is downregulated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide